WANTAI BIOLOGICAL(SH:603392) Bei Jing Shang Bao·2025-06-04 13:04Core Viewpoint - Wantai Biological's approval of the nine-valent HPV vaccine marks a potential turning point for the company, which has been facing significant performance pressure [2][7]. Company Summary - Wantai Biological's subsidiary, Xiamen Wantai Canghai Biotechnology Co., Ltd., has received approval for the nine-valent HPV vaccine (brand name: Xinkening 9), making it the first domestically approved nine-valent HPV vaccine in China [2]. - The company has passed the GMP compliance inspection for the production line of the nine-valent HPV vaccine, which is a prerequisite for its market launch [2]. - The nine-valent HPV vaccine covers seven high-risk types (HPV 16/18/31/33/45/52/58) and two low-risk types (HPV 6/11), aimed at preventing related diseases caused by these virus types [5][6]. - The vaccine is suitable for females aged 9 to 45, with a two-dose regimen for ages 9 to 17 and a three-dose regimen for ages 18 to 45 [6]. Industry Summary - The nine-valent HPV vaccine is expected to enhance Wantai Biological's product line and core competitiveness, providing a solid foundation for sustainable development [6]. - The market for high-valent HPV vaccines is anticipated to expand due to increasing public health awareness and consumer purchasing power [6]. - Wantai Biological's financial performance has been under pressure, with a significant decline in revenue and net profit for 2023 and 2024, attributed to market adjustments and government procurement policies [7]. - Other companies, including Shanghai Bowei, Jiangsu Ruike, Watson Bio, and Kangle Health, are also competing in the nine-valent HPV vaccine market, indicating a potential increase in market competition [7].